|Bid||49.00 x 1000|
|Ask||49.10 x 800|
|Day's Range||48.05 - 49.15|
|52 Week Range||31.10 - 59.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.18|
How far off is Syneos Health Inc (NASDAQ:SYNH) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock isRead More...
Syneos Health, Inc. (SYNH) (“Syneos Health” or “the Company”), a leading biopharmaceutical solutions organization, today announced the acquisition of Kinapse, a market leading advisory and operational solutions provider to the global life sciences industry, from Hg, a specialist investor based in the U.K. Established in 2005, Kinapse delivers services across the clinical and commercial lifecycle, and will further enhance Syneos Health’s ability to provide customers with end-to-end solutions to accelerate time to market. Kinapse’s capabilities expand Syneos Health’s regulatory, safety and pharmacovigilance consulting and operations in the post-market arena – outsourcing areas expected to experience double-digit growth.
RALEIGH, N.C., Aug. 17, 2018-- Syneos Health TM, the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO, today announced that Chief Financial Officer Jason Meggs is ...
Syneos Health, Inc. (SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. of an aggregate of 6,000,000 shares of the Company’s common stock at a price to the public of $50.15 per share. Syneos Health will not receive any proceeds from the sale of the shares by the selling stockholders in this offering. Morgan Stanley is acting as the sole underwriter of the offering.
Syneos Health, Inc. (SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that affiliates of Thomas H. Lee Partners, L.P. intend to offer for sale in an underwritten secondary offering 6,000,000 shares of the Company’s common stock (the “Offering”) pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission (“SEC”). Syneos Health will not receive any proceeds from the sale of the shares by the selling stockholders in the Offering. Morgan Stanley is acting as the sole underwriter of the Offering.
Syneos Health (SYNH) delivered earnings and revenue surprises of 3.33% and -0.98%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Raleigh, North Carolina-based company said it had net income of 13 cents per share. Earnings, adjusted for one-time gains and costs, came to 62 cents per share. The results beat Wall Street expectations. ...
GAAP total revenue of $1.07 billion and $2.13 billion for the three and six months ended June 30, 2018, respectively. Combined Company ASC 606 adjusted service revenue of $1.08 billion and $2.14 billion ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Syneos Health, Inc. Class A (NASDAQ: SYNH ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:00 AM Eastern ...
RALEIGH, N.C., July 12, 2018-- Syneos Health™, the only fully integrated biopharmaceutical solutions organization combining a CRO and CCO, will release its second quarter 2018 financial results on Thursday, ...
NEW YORK, July 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of WideOpenWest, ...
LONDON, UK / ACCESSWIRE / June 29, 2018/ If you want a free Stock Review on TMO sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following Medical Laboratories and Research stocks for observation: Syneos Health Inc. (NASDAQ: SYNH), T2 Biosystems Inc. (NASDAQ: TTOO), Thermo Fisher Scientific Inc. (NYSE: TMO), and Bruker Corp. (NASDAQ: BRKR).
The Vienna biotech was awarded $2.9 million in damages, more than four years after filing a breach of contract suit.
InVentiv Health Consulting has filed a lawsuit in federal court against former employees, citing trade secret misappropriation and other allegations.
Syneos Health, Inc. (SYNH) has been on the move lately as the stock has risen by 18.9% in the past four weeks, and it is currently trading well above its 20-Day SMA